The Biden administration has proposed tightening up enforcement of the federal laws that govern requiring mental health parity, a group of statutes that include the watershed Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 and the Consolidated Appropriations Act of 2021, which requires health plans to perform analyses that compare “nonquantitative treatment limits” (NQTLs) on mental and behavioral health benefits with those for medical and surgical services.
NQTLs include rules governing prior authorization, provider reimbursement rates and provider networks. Under the mental health parity laws, the NQTLs for mental and behavioral services are supposed to be no more restrictive than they are medical and surgical services.
If the administration’s new rules are finalized, they would require health plans to supply more detail in their NQTL comparative analyses. The analyses would have to include, for example, new information comparing claims denials for mental and behavioral health services to denials for medical and surgical services.
Health plans might also be facing new requirements to provide data that will allow regulators to compare their networks of mental and behavioral health providers to their networks of medical and surgical providers. One of the main gaps in mental health parity with respect to health insurance has been the shortage of in-network providers.
A July 2023 enforcement report listed several examples of NQTL shortcomings flagged by federal regulators:
Excluding coverage of residential treatment for mental health and substance use disorders when residential treatment for medical and surgical treatment was covered
Using employee assistance programs (EAPs) as gatekeepers to services for mental health and substance use disorder services when plan members didn’t have go through an EAP to use medical or surgical benefits
Excluding methadone as a treatment for opioid use disorder but covering it for medical and surgical conditions
Not covering inpatient substance use disorder treatment unless the member completes the entire course of treatment when no such requirement exists for medical or surgical treatment.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
A Conversation with Jeremiah Johnson, Executive Director of PrEP4All
July 25th 2025Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the importance of preexposure anaphylaxis and why he’s hesitant to jump on the Lenacapavir breakthrough bandwagon.
Read More
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More